Precision medicine meets public health: population screening for BRCA1 and BRCA2.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of the National Cancer Institute

• Publication date

  2014-12-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/jnci/dju420PMID 25550384
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

  2015cited by this paper
• Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award.

  2014cited by this paper
• Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement.

  2014cited by this paper
• Population Testing for Cancer Predisposing BRCA1/BRCA2 Mutations in the Ashkenazi-Jewish Community: A Randomized Controlled Trial

  2014cited by this paper
• Cost-effectiveness of Population Screening for BRCA Mutations in Ashkenazi Jewish Women Compared With Family History–Based Testing

  2014cited by this paper
• Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2

  2014cited by this paper
• Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer.

  2014cited by this paper
• Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation.

  2014cited by this paper
• Genetic/familial high-risk assessment: breast and ovarian, version 1.2014.

  2014cited by this paper
• Which screening strategy should be offered to women with BRCA1 or BRCA2 mutations? A simulation of comparative cost-effectiveness

  2013cited by this paper
• Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing

  2011cited by this paper
• Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality

  2011cited by this paper
• Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.

  2010cited by this paper
• Limited family structure and BRCA gene mutation status in single cases of breast cancer.

  2007cited by this paper
• The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention?

  2007cited by this paper
• Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Recommendation Statement

  2005cited by this paper
• Genetic counseling for BRCA1/2: A randomized controlled trial of two strategies to facilitate the education and counseling process

  2005cited by this paper
• Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2

  2003cited by this paper
• Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals.

  2002cited by this paper
• Statement of the American Society of Clinical Oncology : Genetic testing for cancer susceptibility. Commentaries

  1996cited by this paper
• Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996.

  1996cited by this paper

• Expanding Germline Hereditary Cancer Gene Panel Testing by Nongenetics Providers: 3-Year Experience in Large Integrated Health Care Delivery System.

  2025cites this paper
• A Quantitative Approach in Identifying Natural Selection Signals on Biallelic Single Nucleotide Polymorphisms of BRCA1 Gene in Diverse Populations

  2024cites this paper
• Additional findings from the 100,000 Genomes Project: a qualitative study of recipient perspectives.

  2024cites this paper
• Implementation of a Population-Based Cancer Family History Screening Program for Lynch Syndrome

  2023cites this paper
• Genetic Considerations in the Locoregional Management of Breast Cancer: a Review of Current Evidence

  2023cites this paper
• Familiärer Brust- und Eierstockkrebs – verhindern oder früh erkennen?

  2023cites this paper
• Secondary (additional) findings from the 100,000 Genomes Project: disease manifestation, healthcare outcomes and costs of disclosure

  2023cites this paper
• Insights from 25 years of oncogenetics: one person’s perspective

  2023cites this paper
• Brca1 Is Regulated by the Transcription Factor Gata3, and Its Silencing Promotes Neural Differentiation in Retinal Neurons

  2022cites this paper
• Predominance of BRCA2 Mutation and Estrogen Receptor Positivity in Unselected Breast Cancer with BRCA1 or BRCA2 Mutation

  2022cites this paper
• Evaluation of two population screening programmes for BRCA1/2 founder mutations in the Australian Jewish community: a protocol paper

  2021cites this paper
• Targeted BRCA1/2 population screening among Ashkenazi Jewish individuals using a web-enabled medical model: An observational cohort study.

  2021cites this paper
• Profile of Pathogenic Mutations and Evaluation of Germline Genetic Testing Criteria in Consecutive Breast Cancer Patients Treated at a North Indian Tertiary Care Center

  2021cites this paper
• Revisiting Secondary Information Related to Pharmacogenetic Testing

  2021cites this paper
• Uptake of genetic counseling and testing in a clinic‐based population of women with breast cancer

  2021cites this paper
• Expanding the search for germline pathogenic variants for breast cancer. How far should we go and how high should we jump? The missed opportunity!

  2021cites this paper
• Racial Disparities in Breast Cancer and Genomic Uncertainty: A QuantCrit Mini-Review

  2020cites this paper
• The contemporary landscape of genetic testing and breast cancer: Emerging issues

  2020cites this paper
• Knowledge, Attitudes, Willingness to Pay, and Patient Preferences About Genetic Testing and Subsequent Risk Management for Cancer Prevention

  2020cites this paper
• BRCA testing in unaffected young women in the United States, 2006‐2017

  2020cites this paper
• Universelle genetische Testungen gegen die Unterdiagnose von erblichem Brustkrebs

  2019cites this paper
• A Pragmatic Testing-Eligibility Framework for Population Mutation Screening: The Example of BRCA1/2

  2019cites this paper
• Universelle genetische Testungen gegen die Unterdiagnose von erblichem Brustkrebs

  2019cites this paper
• Attitude towards and factors affecting uptake of population‐based BRCA testing in the Ashkenazi Jewish population: a cohort study

  2019cites this paper
• Human Mutation

  2019cites this paper
• The spectrum of BRCA1 and BRCA2 pathogenic sequence variants in Middle Eastern, North African, and South European countries

  2019cites this paper
• Diversity in the Era of Precision Medicine - From Bench to Bedside Implementation.

  2019cites this paper
• Aportación de la secuenciación masiva de nueva generación en el diagnóstico del síndrome de cáncer de mama y ovario hereditario mediante el uso de un panel de genes

  2019cites this paper
• A pediatric perspective on genomics and prevention in the twenty-first century

  2019cites this paper
• Knowledge and opinions regarding BRCA1 and BRCA2 genetic testing among primary care physicians

  2019cites this paper
• Current Approaches to Germline Cancer Genetic Testing.

  2019cites this paper
• Updates in Genetic Testing Guidelines for Breast Cancer Susceptibility Genes: a Change in the Paradigm

  2019cites this paper
• Breast Cancer Statistics in the European Union: Incidence and Survival across European Countries

  2019cites this paper
• Genetic testing for BRCA mutations: a policy paper

  2019cites this paper
• Genetic Risk Prediction in Breast Cancer

  2018cites this paper
• Cancer genetics, precision prevention and a call to action

  2018cites this paper
• Exome Sequencing–Based Screening for BRCA1/2 Expected Pathogenic Variants Among Adult Biobank Participants

  2018cites this paper
• Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle?

  2018cites this paper
• Lessons learned from two decades of BRCA1 and BRCA2 genetic testing: the evolution of data sharing and variant classification

  2018cites this paper
• Personalised medicine and population health: breast and ovarian cancer

  2018cites this paper
• Underdiagnosis of Hereditary Breast and Ovarian Cancer in Medicare Patients: Genetic Testing Criteria Miss the Mark

  2018cites this paper
• Precision Medicine: Functional Advancements.

  2018cites this paper
• Treatment of BRCA1/2-associated breast cancer and identification of mutation carriers among breast cancer patients

  2017cites this paper
• Is there evidence that we should screen the general population for Lynch syndrome with genetic testing? A systematic review

  2017cites this paper
• Deciding about statins : a qualitative study of the way people come to take longterm preventive medication

  2017cites this paper
• A Simulation Study on Hypothetical Ebola Virus Transmission in India Using Spatiotemporal Epidemiological Modeler (STEM): A Way towards Precision Public Health

  2017cites this paper
• Risk Assessment for Breast Cancer

  2017cites this paper
• Anticipated health behaviour changes and perceived control in response to disclosure of genetic risk of breast and ovarian cancer: a quantitative survey study among women in the UK

  2017cites this paper
• Treatment of BRCA 1 / 2-associated breast cancer and identification of mutation carriers among breast cancer patients

  2017cites this paper
• BRCA Testing by Single-Molecule Molecular Inversion Probes.

  2017cites this paper
• Cost‐effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry

  2017cites this paper
• Accelerated geroncogenesis in hereditary breast-ovarian cancer syndrome

  2016cites this paper
• Physician knowledge and attitudes concerning breast cancer genetics

  2016cites this paper
• The future of clinical cancer genomics.

  2016cites this paper
• Sanger Sequencing for BRCA1 c.68_69del, BRCA1 c.5266dup and BRCA2 c.5946del Mutation Screen on Pap Smear Cytology Samples

  2016cites this paper
• The clinical utility of molecular genetic cancer profiling

  2016cites this paper
• Genetic screening for gynecological cancer: where are we heading?

  2016cites this paper
• Randomized Noninferiority Trial of Telephone Delivery of BRCA1/2 Genetic Counseling Compared With In-Person Counseling: 1-Year Follow-Up.

  2016cites this paper
• Current conditions or future risks: certainty and uncertainty in decisions about statins

  2016cites this paper
• Population screening for hereditary cancer syndromes: opinions from Amazon Mechanical Turks

  2016cites this paper
• Community attitudes towards a Jewish community BRCA1/2 testing program

  2016cites this paper
• Improving Decision Making about Genetic Testing in the Clinic: An Overview of Effective Knowledge Translation Interventions

  2016cites this paper
• Population-Wide Screening for Germline BRCA1 and BRCA2 Mutations: Too Much of a Good Thing?

  2015cites this paper
• Multiple-Gene Panels and the Future of Genetic Testing

  2015cites this paper
• Recent Advances and Emerging Applications in Text and Data Mining for Biomedical Discovery

  2015cites this paper